Abstract
Spontaneous coronary artery dissection (SCAD) is an uncommon condition which is increasingly recognized as a cause of significant morbidity. SCAD can cause acute coronary syndrome and myocardial infarction (MI), as well as sudden cardiac death. It presents similarly to atherosclerotic MI although typically in patients with few or no atherosclerotic risk factors, and particularly in women. As more patients are recognized to have this condition, there is a great need for clinician familiarity with diagnostic criteria, as well as with contemporary treatment approaches, and with appropriate patient-centered counseling, including genetic testing, exercise recommendations, and psychological care. The standard of care for patients with SCAD is rapidly evolving. This review therefore summarizes the diagnosis of SCAD, epidemiology, modern treatment, cardiac rehabilitation and preconception counseling, and the current approach to genetic testing, exercise recommendations, and psychological care, all of which are crucial to the vascular medicine specialist.
Introduction
Spontaneous coronary artery dissection (SCAD) was first recognized in 1931 (1) and is an uncommon but important cause of myocardial infarction (MI), particularly in young people (1). It causes less than 1% of MI in some cohorts although it is likely underdiagnosed despite recent efforts at increasing awareness (2). SCAD occurs primarily in women who may not have traditional risk factors for atherosclerotic coronary artery disease and causes 25%–30% of MI in women younger than 50 years of age, as well as 15%–20% of peripartum and pregnancy-associated MI (3–7). Its pathophysiology is incompletely understood, but it probably results from dissection of the tunica media or rupture of the vasavasorum, causing intramural hemorrhage and hematoma and resultant luminal obstruction by the dissection flap or the hematoma itself. This may result in ischemia or infarction (8, 9). Prompt diagnosis is essential, as treatment differs considerably from the more common causes of MI, and SCAD is associated with high rates of complications (2). Further, SCAD highlights a vascular system at risk of further dissection, and it is linked to other vasculopathies such as fibromuscular dysplasia (FMD) and aneurysms (10, 11). A diagnosis should prompt diagnostic imaging of other vascular territories to identify aneurysms or extra-coronary abnormalities requiring treatment and referral to a vascular specialist (12). Patients may also benefit from lifestyle counseling to decrease the risk of recurrence (12). This review will discuss the clinical manifestations and various types of SCAD, diagnostic findings, surveillance for disease in the non-coronary vasculature, pharmacologic management, genetic testing, and advice for patients, particularly for patients considering pregnancy. As SCAD may be the initial presentation of an underlying vascular disease, vascular specialists should be familiar with the rapidly evolving science of SCAD, including its epidemiology, diagnosis, treatment, and the patient counseling required in this condition.
Clinical presentation
The clinical presentation of SCAD is similar to MI caused by atherosclerotic coronary artery disease and can encompass all the signs and symptoms of the acute coronary syndrome (13, 14). In one study, 30% of patients presented after physical exertion, and half presented after emotional stress, although it is important to note that no cause of SCAD is found in many patients (14). There is also an association with increased shear stress, such as with exercise, sneezing, or cocaine use (12). Because it may present as unstable angina or even as cardiac arrest, a high index of suspicion is required to make the diagnosis, particularly as patients typically have no or few risk factors for atherosclerotic disease (15).
Diagnosis
Coronary angiography
While the most commonly affected artery is the left anterior descending artery (LAD) (16, 17), SCAD can affect any coronary artery and is diagnosed via coronary angiography. Four sub-types may be visualized (Table 1) (18). Type 1 is illustrated by multiple lumens and a visible flap. Type 2 is the most common, with abrupt luminal narrowing without flap (Figures 1A,B). Type 3 causes gradual luminal narrowing without a visible flap (Figure 1C). Intracoronary nitroglycerin may be helpful to rule out coronary vasospasm as a cause of these various findings, particularly when SCAD types 2 or 3 are suspected (18).
Table 1
| Classification | Angiographic appearance |
|---|---|
| Type 1 | Multiple lumens visible, with an intervening flap, due to contrast traversing both false and true lumens |
| Type 2A | Abrupt luminal narrowing without flap, due to intramural hematoma. Stenosis terminates in normal artery. |
| Type 2B | Abrupt luminal narrowing without flap, due to intramural hematoma. Stenosis continues to end of artery. |
| Type 3 | Gradual luminal narrowing without flap, due to intramural hematoma, often indistinguishable from atherosclerosis. Usually less than 20 mm in length. |
Classification of SCAD phenotypes by angiography (18).
Figure 1
CENTRAL ILLUSTRATION
Traditional coronary angiography may not be sufficient to make the diagnosis, particularly when a dissection flap is not visible, such as in type 3 dissection. In these cases, intracoronary imaging with intravascular ultrasound (IVUS) or optical coherence tomography (OCT) is instrumental. These modalities, however, carry a theoretical risk of dissection propagation. However, the benefits of diagnostic precision and precise treatment must be weighed against this theoretical risk. It is important to note that in recent studies on intracoronary imaging in MINOCA, no such complications occurred (19).
Computed tomography angiography
Coronary computed tomography angiography (CCTA) can reveal intramural hematoma or dissection flap in proximal vessels, as well as perfusion defects, which, if present, can suggest SCAD (20, 21). It is not yet a widely accepted tool, as it cannot rule out SCAD due to resolution limitations, and a case-control study showed that its early use did not reduce death or subsequent MI (22, 23). It may be useful, however, in follow up to clarify if dissected vessels are healing, and in evaluation for anatomic features of the coronary arteries (such as shortened left main and an acute angle between the LAD and the first diagonal branch), which, if present, may cause an increased risk of SCAD due to increased vessel shear stress (24, 25). If CCTA is chosen, protocols with lower doses of radiation should be used as these patients tend to be younger, and more often female (26).
Epidemiology and pathophysiology
Compared to patients with MI caused by atherosclerosis, patients with SCAD are much more likely to be female, younger, and have fewer risk factors for atherosclerotic disease (14, 17). Almost 90% of patients are female, commonly aged 47–53 years (16, 27, 28). Further, SCAD causes 15%–20% of MI during pregnancy or the peripartum period (3, 29). The reason for this sex predilection is unclear.
SCAD is associated with pregnancy, known as P-SCAD. It affects 1.81 per 100,000 pregnancies, with 70% occurring postpartum (30), usually within the first week (30), and these patients tend to have more severe presentations (30, 31). 1/3 of P-SCAD cases occur in late pregnancy and 2/3 in the early postpartum period (16, 32), and P-SCAD accounts for <5%–17% of SCAD cases overall and 14.5%–43% of pregnancy-associated AMI (2, 14, 18, 33, 34). SCAD has also been associated with multiparity (35–37), clomiphene (35), oral contraceptives (7, 37, 38), and hormone replacement therapy (7, 37, 38). Why it presents often in the peripartum period is unclear, but it could be linked to the hemodynamic changes of pregnancy such as increased cardiac output and blood volume, and reduced systemic vascular resistance (39). It is also possible that perimenopausal/peripartum hormonal fluctuation changes the quantity of elastic fibers and collagen synthesis, as well as the mucopolysaccharide content of arterial walls (3, 18, 31, 35, 39, 40). For example, one study linked estrogen exposure to increased expression of matrix metalloproteinases (MMPs) from vascular smooth muscle cells, leading to necrosis and an unsupported vasa vasorum (41). Additionally, progesterone levels remain high during pregnancy, which can cause loss of normal corrugation of elastic fibers (42). This process could lead to increased susceptibility of rupture with increased hemodynamic stress, as occurs in pregnancy and labor (41).
SCAD is also closely linked with other vasculopathies such as fibromuscular dysplasia (FMD) and has also been described in collagen-elastic fiber disorders such as Ehlers-Danlos and Marfan syndromes (7, 43–46). There is also an inconsistent association with inflammatory disorders which are in general more common in women (12, 30, 47). Regardless of pathophysiology, mortality risk is lower with acute MI from SCAD (in the non-pregnant state) in comparison to MI associated with atherosclerosis (48). This is likely secondary to younger age and lower prevalence of atherosclerotic risk factors (48).
SCAD and fibromuscular dysplasia
FMD is a noninflammatory, nonatherosclerotic vasculopathy of unclear etiology that is characterized by intima and media hyperplasia, adventitial sclerosis, and destruction of normal elastic tissue. Like SCAD, FMD also primarily affects women. Recent studies have found a significant link between the two conditions (7, 10, 39, 49), especially with concomitant migraines (28, 48). More than 50% of patients with SCAD have FMD, making it the main underlying arterial abnormality observed in SCAD (7, 14, 15, 49). As both conditions are rare, this association suggests causality (39). Because of this strong correlation, all patients with SCAD should undergo screening for FMD with a comprehensive vascular physical examination and with head-to-pelvis CTA (or magnetic resonance angiography, MRA), as finding extra-coronary involvement may affect management and inform prognosis (50). For example, aneurysms or other dissections may require additional treatment to prevent rupture or longitudinal follow up with serial imaging.
Recent advances in genetics have helped to elucidate the link FMD between SCAD. They both appear to be familial in <5% of cases with autosomal dominant inheritance (51). Some studies have revealed common single nucleotide variants, though there is still no explanation as to the sex differences in SCAD (31). The PHACTR1/EDN1 (phosphatase and actin regulator and endothelin 1) locus was the first genetic risk factor to be identified to potentially link SCAD and FMD (52). Further, loss of function of PTGIR (prostaglandin reductase) is enriched in both FMD and SCAD. These mutations seem to lead to non-atherosclerotic arterial stenosis and dissection in patients diagnosed with FMD and SCAD (53).
Post-dissection care
In this section, we enlist a stepwise format to address and recognize some of the patient facing challenges in the management of post-SCAD care. These concerns focus on rehabilitation of patients and return to functional lives. (Central Illustration, Table 2).
Table 2
| Not recommended | Recommended | |
|---|---|---|
| Exercise |
|
|
| Contraception and preconception counseling |
|
|
| Breastfeeding |
| |
| Genetic testing |
|
|
| Cardiac rehabilitation |
| |
| Medical therapy |
|
|
Post dissection care recommendations.
(a) Exercise
It is generally advised that patients with SCAD should avoid prolonged high-intensity activities, competitive and contact sports, activities performed to exhaustion, sudden increases in physical activity, exercise in extreme temperature or terrain, or performance of the Valsalva maneuver during lifting or exercise (12). Though evidence-based research is lacking, this conservative approach is based on successful clinical practice that mimics the cardiac rehabilitation thresholds previously described (54). Low resistance and high repetition exercises are recommended and deemed safe while weight training (1, 55). The theoretical reason for this advice is that high-intensity activities, sudden increases in exertion, extreme environments, and Valsalva maneuvers may increase arterial shear stress and predispose to recurrence of dissection (36).
(b) Contraception and preconception counseling
Data are mixed as to whether repeat pregnancy increases the risk of recurrent SCAD (12, 56). However, due to the risk of mortality and significant morbidity associated with a recurrence, these patients should engage in a multidisciplinary decision-making process about the safety of pregnancy. Many clinicians recommend against pregnancy and encourage the use of contraception. If contraception is chosen, hormonal therapy should be avoided due to studies correlating long-term exposure to progesterone and estrogen with an increased risk for SCAD (2, 36). For patients considering pregnancy, vascular medicine, cardio-obstetrics, and maternal-fetal medicine preconception consultation is advised. Not only is there a potential risk of recurrent SCAD with pregnancy, but also there is accumulating evidence that a recurrent episode can have worse outcomes than the first presentation (12). Patients who do become pregnant after SCAD should be followed longitudinally by a multidisciplinary team of maternal-fetal medicine specialists, cardiologists with experience treating SCAD, and obstetric anesthesiologists throughout the prepartum, intrapartum, and postpartum periods. This team should carefully review the patient's prescribed medicines to ensure all medications are safe for pregnancy, conduct baseline cardiac testing, and create a plan for labor, delivery, and postpartum care (12).
(c) Breastfeeding
Theoretically, hormonal changes during breastfeeding may potentiate the effects of the postpartum period and increase risk for SCAD (57, 58). One study reported that about 3% of women in a cohort were breastfeeding at the time of SCAD (14). However, there is a paucity of data on this specific population, and breastfeeding's potential link to SCAD needs to be investigated further.
(d) Genetic testing
A thorough family history should be obtained. Genetic testing for connective tissue disorders, however, is typically low yield. In one study, it was diagnostic in only 5% of patients (45). Additionally, familial screening is also relatively low yield, with only 1.2% of individuals being recognized (59). Thus, routine genetic screening is not our current practice, although it can be beneficial and should be performed in some cases with a particularly high pre-test probability (37). For example, if other abnormalities are found on echocardiogram such as aortic root dilatation or aneurysms or other arteriopathy on head-to-pelvis imaging, then genetic testing may be helpful, especially among patients with a strong family or personal history suggestive of vasculopathy.
Recently, there have been more advances that link SCAD patients together with underlying genetic mutations (46, 60). Some of these genetic variants have been linked to other forms of arterial diseases, though SCAD is often the first and only presentation. Variants in genes associated with thoracic aortic aneurysm and dissection (TAAD), Loeys-Dietz syndrome (SMAD2), vascular Ehlers-Danlos syndrome (COL3A1), familial thoracic aortic aneurysm and dissection (LOX), and the cytoskeletal protein talin 1 (TLN) have been reported to have increased prevalence in cohorts of SCAD patients (46, 60).
(e) Cardiac rehabilitation and psychological care
Patients have reported physical and emotional benefits from participation in cardiac rehabilitation following SCAD, including improvement in chest pain, exercise capacity, psychosocial well-being, and a reduction in repeat cardiovascular events (54). Standard cardiac rehabilitation beginning 1–2 weeks after SCAD has been deemed safe and improves aerobic capacity, body composition, and measures of depression and stress (61). Cognitive behavioral therapy (CBT) is often part of rehabilitation and has been a successful psychosocial intervention for SCAD survivors. It should be considered as part of the treatment plan for patients experiencing anxiety and depression (62). The primary reason for lack of participation in cardiac rehabilitation and structured psychological support is that these programs are not routinely recommended by healthcare providers (63). In addition to cardiac rehabilitation, other avenues of support should also be considered for patients including counseling, support groups, and patient advocacy organizations.
(f) Medical therapy
Antiplatelet agents
One observational study found that at 1-year-follow up, SCAD patients on dual antiplatelet therapy (DAPT) had a higher rate of adverse cardiovascular events, including death, non-fatal MI, unplanned percutaneous coronary intervention (PCI), and bleeding, when compared with single antiplatelet (SAPT) regimens (64). This study was purely observational, but there is still a risk of bleeding with antiplatelet therapies and limited data on long-term benefit. Further, the patients treated with DAPT rather than SAPT may have had more severe presentations of disease. However, despite these limitations, the current evidence does not support dual antiplatelet therapy.
Statins
Statins are commonly prescribed after MI (65). However, in patients who are subsequently found to have SCAD rather than atherosclerotic coronary disease, statin therapy is likely not necessary unless the patient meets criteria for a statin for other reasons. Post-event comprehensive vascular imaging (e.g., head-to-pelvis CTA) can be helpful in decision making if atherosclerosis is detected.
Beta blockers
Beta blockers are also widely used in the treatment of SCAD, and although routine practice includes the use of beta blockers for SCAD patients, there are no current studies about beta-blocker usage specifically with this population (37). Theoretically, beta blockers may alleviate symptoms, decrease myocardial demand and vessel wall stress, and prevent recurrence (37). These theoretical benefits may indeed be clinically relevant, as a recent study demonstrated markedly reduced SCAD recurrence (hazard ratio 0.36) with beta blockers (66). Beta blockers have the added benefit of reducing the frequency of migraines, which are common among SCAD patients. Counseling patients on possible side effects of beta blockade is important, as fatigue and hypotension are common, which may dramatically affect patients with SCAD, as they are typically young and otherwise healthy without hypertension (12).
Antianginal therapy
Patients commonly experience angina after SCAD (30, 54). A careful history and physical examination are essential when a patient presents with chest pain post-SCAD, particularly looking for signs of in-stent restenosis (if stenting was performed) or SCAD recurrence. Physicians should be aware that women are less likely than men to be treated with anti-anginal therapy. Further, in those reporting angina, women were less likely than men to undergo an exercise ECG, to be referred for coronary angiography, to be prescribed antiplatelet and statin therapies, and to be revascularized, even after multivariable adjustment (67). Physicians must be aware of the potential for cognitive bias when treating women and when choosing whether to evaluate angina with advanced imaging studies (68, 69).
Role of revascularization
Revascularization with PCI or coronary artery bypass grafting has previously been associated with greater failure rates and major adverse cardiovascular event rates (70, 71). However, a recent meta-analysis concluded that there might not be such a drastic difference in outcomes as previously thought (72). When comparing patients managed with the two approaches, no statistically significant difference in death, MI, revascularization, SCAD recurrence, or heart failure was found. Therefore, conservative management with long-term observation should remain the standard of care unless the patient presents with other high-risk features (71, 73) warranting immediate revascularization such as unremitting chest pain or hemodynamic instability.
Current clinical trials
Currently, there is one clinical trial specifically looking at the SCAD population. It is a randomized, controlled clinical trial examining the efficacy beta blockers and antiplatelet agents. The primary completion date for the trial is 2024 (74).
Conclusion
SCAD is a relatively rare form of vascular disease accounting for about 1% of MI and it primarily occurs in women 30–50 years of age. Knowledge of diagnosis and treatment strategies for these patients is crucial for all vascular clinicians. Prompt diagnosis is essential, which should be done with either IVUS or OCT. Non-pregnancy associated SCAD most often occurs in the LAD, while pregnancy-associated SCAD is typically multi-vessel. It is typically treated with antiplatelet therapy and beta blockers, though there is increasing evidence that a more robust combination of post-dissection care is useful. This may include revascularization in rare cases, tailored exercise recommendations, cardiac rehabilitation, and preconception counseling for those considering pregnancy. Clinicians should also be aware of the overlap between FMD and SCAD. SCAD is often misdiagnosed, which can lead to worse outcomes for these patients. Close longitudinal follow-up is essential for patients following SCAD, especially as treatment options continue to evolve. Ongoing clinical trials should shed further light on ideal management strategies in this patient population.
Statements
Author contributions
KM: Writing – original draft, Writing – review & editing. BG: Writing – review & editing. ER: Writing – review & editing. EK: Writing – review & editing. GS: Writing – review & editing.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article.
GS is supported by AHA 979462.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
PrettyHC. Dissecting aneurysm of coronary artery in a woman aged 42. Br Med J. (1931) 1(3667):667.
2.
TweetMSHayesSNPittaSRSimariRDLermanALennonRJet alClinical features, management, and prognosis of spontaneous coronary artery dissection. Circulation. (2012) 126(5):579–88. 10.1161/CIRCULATIONAHA.112.105718
3.
ElkayamUJalnapurkarSBarakkatMNKhatriNKealeyAJMehraAet alPregnancy-associated acute myocardial infarction: a review of contemporary experience in 150 cases between 2006 and 2011. Circulation. (2014) 129(16):1695–702. 10.1161/CIRCULATIONAHA.113.002054
4.
NakashimaTNoguchiTHarutaSYamamotoYOshimaSNakaoKet alPrognostic impact of spontaneous coronary artery dissection in young female patients with acute myocardial infarction: a report from the angina pectoris-myocardial infarction multicenter investigators in Japan. Int J Cardiol. (2016) 207:341–8. 10.1016/j.ijcard.2016.01.188
5.
FadenMSBottegaNBenjaminABrownRN. A nationwide evaluation of spontaneous coronary artery dissection in pregnancy and the puerperium. Heart. (2016) 102(24):1974–9. 10.1136/heartjnl-2016-309403
6.
SawJAymongEManciniGBSedlakTStarovoytovARicciD. Nonatherosclerotic coronary artery disease in young women. Can J Cardiol. (2014) 30(7):814–9. 10.1016/j.cjca.2014.01.011
7.
StanojevicDApostolovicSKosticTMitovVKutlesic-KurtovicDKovacevicMet alA review of the risk and precipitating factors for spontaneous coronary artery dissection. Front Cardiovasc Med. (2023) 10:1273301. 10.3389/fcvm.2023.1273301
8.
DesaiSSheppardMN. Sudden cardiac death: look closely at the coronaries for spontaneous dissection which can be missed. A study of 9 cases. Am J Forensic Med Pathol. (2012) 33(1):26–9. 10.1097/PAF.0b013e3181e29598
9.
HillSFSheppardMN. Non-atherosclerotic coronary artery disease associated with sudden cardiac death. Heart. (2010) 96(14):1119–25. 10.1136/hrt.2009.185157
10.
SawJRicciDStarovoytovAFoxRBullerCE. Spontaneous coronary artery dissection: prevalence of predisposing conditions including fibromuscular dysplasia in a tertiary center cohort. JACC Cardiovasc Interv. (2013) 6(1):44–52. 10.1016/j.jcin.2012.08.017
11.
SawJPoulterRFungAWoodDHamburgerJBullerCE. Spontaneous coronary artery dissection in patients with fibromuscular dysplasia: a case series. Circ Cardiovasc Interv. (2012) 5(1):134–7. 10.1161/CIRCINTERVENTIONS.111.966630
12.
HayesSNKimESHSawJAdlamDArslanian-EngorenCEconomyKEet alSpontaneous coronary artery dissection: current state of the science: a scientific statement from the American Heart Association. Circulation. (2018) 137(19):e523–e57. 10.1161/CIR.0000000000000564
13.
LuongCStarovoytovAHeydariMSedlakTAymongESawJ. Clinical presentation of patients with spontaneous coronary artery dissection. Catheter Cardiovasc Interv. (2017) 89(7):1149–54. 10.1002/ccd.26977
14.
SawJStarovoytovAHumphriesKShethTSoDMinhasKet alCanadian spontaneous coronary artery dissection cohort study: in-hospital and 30-day outcomes. Eur Heart J. (2019) 40(15):1188–97. 10.1093/eurheartj/ehz007
15.
TweetMSGulatiRHayesSN. What clinicians should know about spontaneous coronary artery dissection. Mayo Clin Proc. (2015) 90(8):1125–30. 10.1016/j.mayocp.2015.05.010
16.
VrintsCJ. Spontaneous coronary artery dissection. Heart. (2010) 96(10):801–8. 10.1136/hrt.2008.162073
17.
MortensenKHThuesenLKristensenIBChristiansenEH. Spontaneous coronary artery dissection: a Western Denmark Heart Registry study. Catheter Cardiovasc Interv. (2009) 74(5):710–7. 10.1002/ccd.22115
18.
SawJ. Coronary angiogram classification of spontaneous coronary artery dissection. Catheter Cardiovasc Interv. (2014) 84(7):1115–22. 10.1002/ccd.25293
19.
ReynoldsHRMaeharaAKwongRYSedlakTSawJSmilowitzNRet alCoronary optical coherence tomography and cardiac magnetic resonance imaging to determine underlying causes of myocardial infarction with nonobstructive coronary arteries in women. Circulation. (2021) 143(7):624–40. 10.1161/CIRCULATIONAHA.120.052008
20.
Pozo-OsinaldeEGarcía-GuimaraesMBastanteTAguileraMCRodríguez-AlcudiaDRiveroFet alCharacteristic findings of acute spontaneous coronary artery dissection by cardiac computed tomography. Coron Artery Dis. (2020) 31(3):293–9. 10.1097/MCA.0000000000000819
21.
AslamAStojanovskaJKhokharUSWeinbergRLGaneshSKLabountyTet alSpontaneous coronary artery dissection: an underdiagnosed clinical entity—a primer for cardiac imagers. Radiographics. (2021) 41(7):1897–915. 10.1148/rg.2021210062
22.
LindeJJKelbækHHansenTFSigvardsenPETorp-PedersenCBechJet alCoronary CT angiography in patients with non-ST-segment elevation acute coronary syndrome. J Am Coll Cardiol. (2020) 75(5):453–63. 10.1016/j.jacc.2019.12.012
23.
GrayAJRoobottomCSmithJEGoodacreSOateyKO'BrienRet alThe RAPID-CTCA trial (rapid assessment of potential ischaemic heart disease with CTCA)—a multicentre parallel-group randomised trial to compare early computerised tomography coronary angiography versus standard care in patients presenting with suspected or confirmed acute coronary syndrome: study protocol for a randomised controlled trial. Trials. (2016) 17(1):579. 10.1186/s13063-016-1717-2
24.
Bin SaeedanMRamchandJBolenM. Role of computed tomography angiography in setting of spontaneous coronary artery dissection. Curr Probl Diagn Radiol. (2021) 50(4):532–9. 10.1067/j.cpradiol.2020.07.010
25.
Di DonnaCCavalloAUPuglieseLRicciFDe StasioVPresicceMet alAnatomic features in SCAD assessed by CCT: a propensity score matching case control study. Ann Cardiol Angeiol (Paris). (2021) 70(3):161–7. 10.1016/j.ancard.2021.01.003
26.
GudenkaufBHaysAGTamis-HollandJTrostJAmbinderDIWuKCet alRole of multimodality imaging in the assessment of myocardial infarction with nonobstructive coronary arteries: beyond conventional coronary angiography. J Am Heart Assoc. (2022) 11(1):e022787. 10.1161/JAHA.121.022787
27.
LettieriCZavalloniDRossiniRMoriciNEttoriFLeonziOet alManagement and long-term prognosis of spontaneous coronary artery dissection. Am J Cardiol. (2015) 116(1):66–73. 10.1016/j.amjcard.2015.03.039
28.
KokSNHayesSNCutrerFMRaphaelCEGulatiRBestPJMet alPrevalence and clinical factors of migraine in patients with spontaneous coronary artery dissection. J Am Heart Assoc. (2018) 7(24):e010140. 10.1161/JAHA.118.010140
29.
SmilowitzNRGuptaNGuoYZhongJWeinbergCRReynoldsHRet alAcute myocardial infarction during pregnancy and the puerperium in the United States. Mayo Clin Proc. (2018) 93(10):1404–14. 10.1016/j.mayocp.2018.04.019
30.
TweetMSHayesSNCodsiEGulatiRRoseCHBestPJM. Spontaneous coronary artery dissection associated with pregnancy. J Am Coll Cardiol. (2017) 70(4):426–35. 10.1016/j.jacc.2017.05.055
31.
HayesSNTweetMSAdlamDKimESHGulatiRPriceJEet alSpontaneous coronary artery dissection: JACC state-of-the-art review. J Am Coll Cardiol. (2020) 76(8):961–84. 10.1016/j.jacc.2020.05.084
32.
ChutaniSK. Spontaneous coronary artery dissection in the postpartum period: a pregnancy related phenomenon. Cath Lab Digest. (2014) 22(9).
33.
SharmaSKaadanMIDuranJMPonziniFMishraSTsiarasSVet alRisk factors, imaging findings, and sex differences in spontaneous coronary artery dissection. Am J Cardiol. (2019) 123(11):1783–7. 10.1016/j.amjcard.2019.02.040
34.
NishiguchiTTanakaAOzakiYTaruyaAFukudaSTaguchiHet alPrevalence of spontaneous coronary artery dissection in patients with acute coronary syndrome. Eur Heart J Acute Cardiovasc Care. (2016) 5(3):263–70. 10.1177/2048872613504310
35.
AbuzeyadFHIbnaoufESFarrasMA. Clomiphene associated inferior STEMI in a young female due to right coronary artery dissection. Case Rep Emerg Med. (2017) 2017:4747831. 10.1155/2017/4747831
36.
SawJAymongESedlakTBullerCEStarovoytovARicciDet alSpontaneous coronary artery dissection: association with predisposing arteriopathies and precipitating stressors and cardiovascular outcomes. Circ Cardiovasc Interv. (2014) 7(5):645–55. 10.1161/CIRCINTERVENTIONS.114.001760
37.
SawJManciniGBJHumphriesKH. Contemporary review on spontaneous coronary artery dissection. J Am Coll Cardiol. (2016) 68(3):297–312. 10.1016/j.jacc.2016.05.034
38.
EngLStarovoytovAHeydariMSawJ. Abstract 18913: spontaneous coronary artery dissection in women and association with hormonal stressors. Circulation. (2015) 132:A18913. 10.1161/circ.132.suppl_3.18913
39.
YipASawJ. Spontaneous coronary artery dissection—a review. Cardiovasc Diagn Ther. (2015) 5(1):37–48. 10.3978/j.issn.2223-3652.2015.01.08
40.
De MartinoMGovindA. SCAD: a gendered cardiac threat. J Obstet Gynaecol. (2020) 40(7):1027–8. 10.1080/01443615.2019.1677578
41.
WingroveCSGarrEGodslandIFStevensonJC. 17beta-oestradiol Enhances release of matrix metalloproteinase-2 from human vascular smooth muscle cells. Biochim Biophys Acta. (1998) 1406(2):169–74. 10.1016/S0925-4439(97)00097-5
42.
Manalo-EstrellaPBarkerAE. Histopathologic findings in human aortic media associated with pregnancy. Arch Pathol. (1967) 83(4):336–41.
43.
KrittanawongCKumarAJohnsonKWLuoYYueBWangZet alConditions and factors associated with spontaneous coronary artery dissection (from a national population-based cohort study). Am J Cardiol. (2019) 123(2):249–53. 10.1016/j.amjcard.2018.10.012
44.
JudgeDPDietzHC. Marfan’s syndrome. Lancet. (2005) 366(9501):1965–76. 10.1016/S0140-6736(05)67789-6
45.
HenkinSNegrottoSMTweetMSKirmaniSDeyleDRGulatiRet alSpontaneous coronary artery dissection and its association with heritable connective tissue disorders. Heart. (2016) 102(11):876–81. 10.1136/heartjnl-2015-308645
46.
KatzAEGaneshSK. Advancements in the genetics of spontaneous coronary artery dissection. Curr Cardiol Rep. (2023) 25(12):1735–43. 10.1007/s11886-023-01989-1
47.
AdlamDAlfonsoFMaasAVrintsCCommitteeW. European Society of Cardiology, Acute Cardiovascular Care Association, SCAD study group: a position paper on spontaneous coronary artery dissection. Eur Heart J. (2018) 39(36):3353–68. 10.1093/eurheartj/ehy080
48.
ClareRDuanLPhanDMooreNJorgensenMIchiujiAet alCharacteristics and clinical outcomes of patients with spontaneous coronary artery dissection. J Am Heart Assoc. (2019) 8(10):e012570. 10.1161/JAHA.119.012570
49.
PrasadMTweetMSHayesSNLengSLiangJJEleidMFet alPrevalence of extracoronary vascular abnormalities and fibromuscular dysplasia in patients with spontaneous coronary artery dissection. Am J Cardiol. (2015) 115(12):1672–7. 10.1016/j.amjcard.2015.03.011
50.
SharmaSRautNPotdarA. Spontaneous coronary artery dissection: case series and review of literature. Indian Heart J. (2016) 68(4):480–5. 10.1016/j.ihj.2015.11.039
51.
MettingerKLEricsonK. Fibromuscular dysplasia and the brain. I. Observations on angiographic, clinical and genetic characteristics. Stroke. (1982) 13(1):46–52. 10.1161/01.STR.13.1.46
52.
AdlamDOlsonTMCombaretNKovacicJCIismaaSEAl-HussainiAet alAssociation of the PHACTR1/EDN1 genetic locus with spontaneous coronary artery dissection. J Am Coll Cardiol. (2019) 73(1):58–66. 10.1016/j.jacc.2018.09.085
53.
GeorgesAAlbuissonJBerrandouTDupréDLorthioirAD'EscamardVet alRare loss-of-function mutations of PTGIR are enriched in fibromuscular dysplasia. Cardiovasc Res. (2021) 117(4):1154–65. 10.1093/cvr/cvaa161
54.
ChouAYPrakashRRajalaJBirnieTIsserowSTaylorCMet alThe first dedicated cardiac rehabilitation program for patients with spontaneous coronary artery dissection: description and initial results. Can J Cardiol. (2016) 32(4):554–60. 10.1016/j.cjca.2016.01.009
55.
SivamSYozghatlianVDenticeRMcGradyMMoriartyCDi MichielJet alSpontaneous coronary artery dissection associated with coughing. J Cyst Fibros. (2014) 13(2):235–7. 10.1016/j.jcf.2013.10.003
56.
TweetMSYoungKABestPJMHyunMGulatiRRoseCHet alAssociation of pregnancy with recurrence of spontaneous coronary artery dissection among women with prior coronary artery dissection. JAMA Netw Open. (2020) 3(9):e2018170. 10.1001/jamanetworkopen.2020.18170
57.
LabbokMH. Effects of breastfeeding on the mother. Pediatr Clin North Am. (2001) 48(1):143–58. 10.1016/S0031-3955(05)70290-X
58.
TakeuchiMOkadaTIkegamiYNakamotoYIdeiNOhashiN. A breastfeeding woman with spontaneous coronary artery dissection and possible takotsubo syndrome: a case report. Medicine (Baltimore). (2021) 100(18):e25775. 10.1097/MD.0000000000025775
59.
GoelKTweetMOlsonTMMaleszewskiJJGulatiRHayesSN. Familial spontaneous coronary artery dissection: evidence for genetic susceptibility. JAMA Intern Med. (2015) 175(5):821–6. 10.1001/jamainternmed.2014.8307
60.
AdlamDBerrandouTEGeorgesANelsonCPGiannoulatouEHenryJet alGenome-wide association meta-analysis of spontaneous coronary artery dissection identifies risk variants and genes related to artery integrity and tissue-mediated coagulation. Nat Genet. (2023) 55(6):964–72. 10.1038/s41588-023-01410-1
61.
SilberTCTweetMSBowmanMJHayesSNSquiresRW. Cardiac rehabilitation after spontaneous coronary artery dissection. J Cardiopulm Rehabil Prev. (2015) 35(5):328–33. 10.1097/HCR.0000000000000111
62.
VacaKCTremmelJAEdwardsKS. Preliminary support for group cognitive behavioral therapy (CBT) to reduce psychological distress in patients with spontaneous coronary artery dissection (SCAD). J Clin Psychol Med Settings. (2021) 28(4):826–32. 10.1007/s10880-021-09803-2
63.
KrittanawongCTweetMSHayesSEBowmanMJGulatiRSquiresRWet alUsefulness of cardiac rehabilitation after spontaneous coronary artery dissection. Am J Cardiol. (2016) 117(10):1604–9. 10.1016/j.amjcard.2016.02.034
64.
CerratoEGiacobbeFQuadriGMacayaFBiancoMMoriRet alAntiplatelet therapy in patients with conservatively managed spontaneous coronary artery dissection from the multicentre DISCO registry. Eur Heart J. (2021) 42(33):3161–71. 10.1093/eurheartj/ehab372
65.
AmsterdamEAWengerNKBrindisRGCaseyDEGaniatsTGHolmesDRet al2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. (2014) 64(24):e139–228. 10.1016/j.jacc.2014.09.017
66.
SawJHumphriesKAymongESedlakTPrakashRStarovoytovAet alSpontaneous coronary artery dissection: clinical outcomes and risk of recurrence. J Am Coll Cardiol. (2017) 70(9):1148–58. 10.1016/j.jacc.2017.06.053
67.
DalyCClemensFLopez SendonJLTavazziLBoersmaEDanchinNet alGender differences in the management and clinical outcome of stable angina. Circulation. (2006) 113(4):490–8. 10.1161/CIRCULATIONAHA.105.561647
68.
DaughertySLBlairIVHavranekEPFurnissADickinsonLMKarimkhaniEet alImplicit gender bias and the use of cardiovascular tests among cardiologists. J Am Heart Assoc. (2017) 6(12):e006872. 10.1161/JAHA.117.006872
69.
OrdovasKG. Invited commentary: enhancing skills for imaging diagnosis of spontaneous coronary artery dissection and other women’s cardiovascular diseases. Radiographics. (2021) 41(7):E200–E1. 10.1148/rg.2021210202
70.
HassanSSamuelRStarovoytovALeeCAymongESawJ. Outcomes of percutaneous coronary intervention in patients with spontaneous coronary artery dissection. J Interv Cardiol. (2021) 2021:6686230. 10.1155/2021/6686230
71.
TweetMSEleidMFBestPJLennonRJLermanARihalCSet alSpontaneous coronary artery dissection: revascularization versus conservative therapy. Circ Cardiovasc Interv. (2014) 7(6):777–86. 10.1161/CIRCINTERVENTIONS.114.001659
72.
JamilATajrishiFZKaheFNajafiHMontazerinSMShojaeiFet alSpontaneous coronary artery dissection managed with a conservative or revascularization approach: a meta-analysis. J Cardiovasc Med (Hagerstown). (2020) 21(1):42–50. 10.2459/JCM.0000000000000891
73.
LawtonJSTamis-HollandJEBangaloreSBatesERBeckieTMBischoffJMet al2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of caRdiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. (2022) 79(2):e21–e129. 10.1016/j.jacc.2021.09.006
74.
AlfonsoFde la Torre HernándezJMIbáñezBSabatéMPanMGulatiRet alRationale and design of the BA-SCAD (Beta-blockers and antiplatelet agents in patients with spontaneous coronary artery dissection) randomized clinical trial. Rev Esp Cardiol (Engl Ed). (2021) 75(6):515–22. 10.1016/j.rec.2021.08.003
Summary
Keywords
SCAD, ACS, pregnancy, acute myocardial infarction, pregnancy associated sudden coronary artery dissection
Citation
Martinez KA, Gudenkauf B, Ratchford EV, Kim ESH and Sharma G (2024) Spontaneous coronary artery dissection: a focus on post-dissection care for the vascular medicine clinician. Front. Cardiovasc. Med. 11:1352700. doi: 10.3389/fcvm.2024.1352700
Received
08 December 2023
Accepted
19 February 2024
Published
20 March 2024
Volume
11 - 2024
Edited by
Maurice Enriquez-Sarano, Minneapolis Heart Institute Foundation (MHIF), United States
Reviewed by
Yaser Jenab, Tehran University of Medical Sciences, Iran
Updates
Copyright
© 2024 Martinez, Gudenkauf, Ratchford, Kim and Sharma.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Garima Sharma garima.sharma@inova.org
Abbreviations AMI, acute myocardial infarction; CBT, cognitive behavioral therapy; CCTA, coronary computed tomography angiography; DAPT, dual antiplatelet therapy; ECG, electrocardiogram; EDN1, endothelin 1; FMD, fibromuscular dysplasia; IVUS, intravascular ultrasound; LAD, left anterior descending artery; MI, myocardial infarction; MMPs, matrix metalloproteinases; MRA, magnetic resonance angiography; OCT, optical coherence tomography; PCI, percutaneous coronary intervention; PHACTR1, phosphatase and actin regulator; P-SCAD, pregnancy associated sudden coronary artery dissection; PTGIR, prostaglandin reductase; SAPT, single antiplatelet therapy; SCAD, sudden coronary artery dissection.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.